Pedro C Barata, Associate Professor at University Hospitals Seidman Cancer Center, shared on LinkedIn:
“Antibody-drug conjugates (ADCs) are rapidly shifting into frontline advanced and curative-intent settings. But with this progress comes critical clinical questions: How do we sequence them? How do we select the right targets? And how do we navigate cross-resistance?
In the latest episode of the ASCO Education: By the Book Podcast, I sat down with Dr. Giuseppe Curigliano of the University of Milan and the European Institute of Oncology to tackle these exact challenges.
Listen to our full discussion on optimizing frontline ADCs.”
Other articles featuring Pedro C Barata on OncoDaily.